Novartis Says New Zolgensma Demonstrate Age-Appropriate Development When Used Presymptomatically And Rapid, Clinically Meaningful Efficacy In Symptomatic Children, Even Those With Severe SMA At Baseline
New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
All children (100%)
